% | $
Quotes you view appear here for quick access.

Arch Therapeutics, Inc. Message Board

kar26dav 18 posts  |  Last Activity: Nov 12, 2015 9:30 AM Member since: Nov 18, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • kar26dav by kar26dav Nov 12, 2015 9:30 AM Flag

    BEACON FALLS — The consensus among those that turned out for a public hearing last week on the proposed Beacon Falls Energy Park was the project would be a boon for the town( they have to Dec 5th hear anymore written concerns and than they will have to vote) It's not a slam dunk yet but it's work in progress.

  • kar26dav by kar26dav Nov 9, 2015 8:10 AM Flag

    WHIPPANY, N.J., Nov. 9, 2015 /PRNewswire/ -- Pazoo, Inc. (OTC Pinks: PZOO) (German WKN#: A1J3DK), is pleased to announce that Pazoo is now generating revenue under a consulting agreement from the operations of a marijuana testing lab. Pazoo last week signed the operational advisory agreement directly with Harris Lee Colorado, LLC (HLCO) for the Denver Colorado marijuana testing laboratory.

    Pazoo, through wholly-owned subsidiary Harris Lee, LLC will begin to earn a fee per test once the transfer of ownership of the Denver testing lab is completed to Harris Lee Colorado. Pazoo currently is also earning a consulting fee during this interim step of HLCO as being the advisory manager and advisor on the proper marketing, sales, testing and overall management of the facility. The final approval from the MED for the complete transfer of the license is expected soon.

  • Reply to

    Dr Joass,.

    by kar26dav Nov 6, 2015 12:42 PM
    kar26dav kar26dav Nov 6, 2015 1:22 PM Flag

    oh , so sorry forgot to mention Falmingmoron. How

  • kar26dav by kar26dav Nov 6, 2015 12:42 PM Flag

    You can say what you want but a 20 year deal is 20 years!...........FuelCell Energy and County of Alameda Announce 20-Year Power Purchase Agreement for a Multi-megawatt Fuel Cell Power Plant at Santa Rita Jail

  • The OMEGA Seamaster 300 "SPECTRE" Limited Edition will be worn by Daniel Craig in his upcoming role as James Bond in the 24th instalment of the film series, SPECTRE.

    "The watch features a bi-directional, rotating diving bezel, made from black, polished ceramic, combined with a LiquidMetal® 12 hour scale, so that time can be kept with any country in the world."

    The actor recently visited the OMEGA factory in Villeret, Switzerland, where he witnessed the production of the Seamaster 300 "SPECTRE" Limited Edition. Craig was impressed by the production of the watch, "To see the engineering that goes into it and legacy that goes into it, that's what fascinated me."

    Looking to take advantage of the unique properties of Liquidmetal alloys, Swatch Group became a licensee of Liquidmetal technology in 2009. Liquidmetal alloy is now featured in several OMEGA watches, predominantly in the Seamaster family. The zirconium-based amorphous metal allows for the blending of ceramic and metal due to its low critical cooling rate, resulting in impressive hardness and corrosion resistance.

  • Reply to

    Real company with real revenue

    by arnr_singh Nov 5, 2015 8:22 PM
    kar26dav kar26dav Nov 6, 2015 7:11 AM Flag

    The real problem is people are impatience and don't understand how the stock market works. Pazoo will do just fine.

  • Reply to

    New production order

    by joeyknows9x9is81 Oct 20, 2015 8:57 AM
    kar26dav kar26dav Nov 3, 2015 4:32 AM Flag

    Jim, I hope this helps answer your question................Certification can be a useful tool to add credibility, by demonstrating that your product or service meets the expectations of your customers. For some industries, certification is a legal or contractual requirement.

  • From what they see on this board and many others on Yahoo, you earn the right to lose money!

  • Reply to

    PAZOO Website Update

    by arnr_singh Nov 1, 2015 8:13 AM
    kar26dav kar26dav Nov 2, 2015 2:15 PM Flag

    Yes , The website is awesome, ad now we have bashers on the board so you know it's ready to take off!

  • kar26dav by kar26dav Oct 29, 2015 8:13 AM Flag

    Looking good going forward.

  • kar26dav by kar26dav Oct 26, 2015 10:39 AM Flag

    Check out conextios medical .

  • They have done the r&d and now focused on sales.

  • Reply to

    New production order

    by joeyknows9x9is81 Oct 20, 2015 8:57 AM
    kar26dav kar26dav Oct 20, 2015 12:49 PM Flag

    This is what will help when its done..............ISO 9000 certification.

  • New Independent Accountants. The Company's Board of Directors appointed Friedman LLP ("Friedman")

  • Might help.

  • Reply to

    to the longs

    by yessirriesir Sep 12, 2015 12:24 PM
    kar26dav kar26dav Sep 13, 2015 9:07 AM Flag

    It's the Carbon Capture that will boost this company forward. China, India and the US could all benefit from this. Not saying buy or sell, Just saying.

  • Reply to


    by kar26dav Sep 7, 2015 6:42 AM
    kar26dav kar26dav Sep 7, 2015 1:44 PM Flag

    At Flight, doing great thanks , hope you are as well.

  • kar26dav by kar26dav Sep 7, 2015 6:42 AM Flag

    LONDON (Reuters) - Britain's healthcare cost-effectiveness watchdog NICE on Monday recommended use of Merck's immunotherapy drug Keytruda, after the U.S. drugmaker promised to supply it to the state health service at a discounted price.

    The move comes amid controversy over access to costly cancer medicines in the country. On Friday, a fund that helps patients receive cancer drugs not routinely paid for by the National Health Service said it would no longer pay for a number of medicines.

    In the case of Merck's drug, the National Institute for Health and Care Excellence (NICE) said in final draft guidance that it should made available for certain patients with advanced melanoma.

    The drug costs about $150,000 for a year of treatment in the United States but will sell for less in Britain. The scale of the discount being offered to Britain's health service is commercially confidential, NICE said.

    Keytruda is a so-called anti PD-1 inhibitor, which works by making cancer cells ‘visible’ to the immune system and so open to attack. The drug received a speedy assessment in Britain under a recently introduced early access scheme for promising new treatments.

    (Reporting by Ben Hirschler; Editing by Mark Potter)

0.18-0.02(-9.32%)Nov 27 12:56 PMEST